Literature DB >> 19558544

Agonist-specific patterns of beta 2-adrenoceptor responses in human airway cells during prolonged exposure.

Caroline Düringer1, Gunilla Grundström, Eylem Gürcan, Ian A Dainty, Mandy Lawson, Solange H Korn, Anders Jerre, Hanna Falk Håkansson, Elisabet Wieslander, Karin Fredriksson, Carl Magnus Sköld, Magnus Löfdahl, Claes-Göran Löfdahl, David J Nicholls, David S Silberstein.   

Abstract

BACKGROUND AND
PURPOSE: Beta(2)-adrenoceptor agonists (beta(2)-agonists) are important bronchodilators used in the treatment of asthma and chronic obstructive pulmonary disease. At the molecular level, beta(2)-adrenergic agonist stimulation induces desensitization of the beta(2)-adrenoceptor. In this study, we have examined the relationships between initial effect and subsequent reduction of responsiveness to restimulation for a panel of beta(2)-agonists in cellular and in vitro tissue models. EXPERIMENTAL APPROACH: Beta(2)-adrenoceptor-induced responses and subsequent loss of receptor responsiveness were studied in primary human airway smooth muscle cells and bronchial epithelial cells by measuring cAMP production. Receptor responsiveness was compared at equi-effective concentrations, either after continuous incubation for 24 h or after a 1 h pulse exposure followed by a 23 h washout. Key findings were confirmed in guinea pig tracheal preparations in vitro. KEY
RESULTS: There were differences in the reduction of receptor responsiveness in human airway cells and in vitro guinea pig trachea by a panel of beta(2)-agonists. When restimulation occurred immediately after continuous incubation, loss of responsiveness correlated with initial effect for all agonists. After the 1 h pulse exposure, differences between agonists emerged, for example isoprenaline and formoterol induced the least reduction of responsiveness. High lipophilicity was, to some extent, predictive of loss of responsiveness, but other factors appeared to be involved in determining the relationships between effect and subsequent loss of responsiveness for individual agonists. CONCLUSIONS AND IMPLICATIONS: There were clear differences in the ability of different beta(2) agonists to induce loss of receptor responsiveness at equi-effective concentrations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19558544      PMCID: PMC2795237          DOI: 10.1111/j.1476-5381.2009.00262.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

2.  Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo.

Authors:  D I Ball; R T Brittain; R A Coleman; L H Denyer; D Jack; M Johnson; L H Lunts; A T Nials; K E Sheldrick; I F Skidmore
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

3.  Estimation of the efficacy and affinity of the beta 2-adrenoceptor agonist salmeterol in guinea-pig trachea.

Authors:  I G Dougall; D Harper; D M Jackson; P Leff
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

Review 4.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s).

Authors:  S A Green; D A Rathz; A J Schuster; S B Liggett
Journal:  Eur J Pharmacol       Date:  2001-06-15       Impact factor: 4.432

7.  Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol.

Authors:  A T Nials; M J Sumner; M Johnson; R A Coleman
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

8.  Influence of agonist intrinsic activity on the desensitisation of beta2-adrenoceptor-mediated responses in mast cells.

Authors:  Anne-Marie Scola; Lee K Chong; Russell Chess-Williams; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

9.  Dual dopamine D2 receptor and beta2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease: the pre-clinical rationale.

Authors:  I G Dougall; A Young; F Ince; D M Jackson
Journal:  Respir Med       Date:  2003-01       Impact factor: 3.415

10.  Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor.

Authors:  S A Green; A P Spasoff; R A Coleman; M Johnson; S B Liggett
Journal:  J Biol Chem       Date:  1996-09-27       Impact factor: 5.157

View more
  11 in total

Review 1.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 2.  Agonist efficacy and receptor desensitization: from partial truths to a fuller picture.

Authors:  Steven J Charlton
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

3.  GPCR theme editorial.

Authors:  G Milligan; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

4.  Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.

Authors:  Anna K Stalder; Dominik Lott; Daniel S Strasser; Hans G Cruz; Andreas Krause; Peter M A Groenen; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2016-11-15       Impact factor: 4.335

5.  Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation.

Authors:  S Fogli; F Stefanelli; L Picchianti; M Del Re; V Mey; C Bardelli; R Danesi; M C Breschi
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  Salmeterol Efficacy and Bias in the Activation and Kinase-Mediated Desensitization of β2-Adrenergic Receptors.

Authors:  Luis E Gimenez; Faiza Baameur; Sharat J Vayttaden; Richard B Clark
Journal:  Mol Pharmacol       Date:  2015-03-17       Impact factor: 4.436

7.  Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms.

Authors:  P R Cooper; R C Kurten; J Zhang; D J Nicholls; I A Dainty; R A Panettieri
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

8.  Agonist-directed desensitization of the β2-adrenergic receptor.

Authors:  Vasiliy Goral; Yan Jin; Haiyan Sun; Ann M Ferrie; Qi Wu; Ye Fang
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

9.  A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties.

Authors:  Hee-Kyoung Lee; Liuyin Zhang; Misty D Smith; Aleksandra Walewska; Nadeem A Vellore; Riccardo Baron; J Michael McIntosh; H Steve White; Baldomero M Olivera; Grzegorz Bulaj
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

10.  Functional desensitization of the β 2 adrenoceptor is not dependent on agonist efficacy.

Authors:  Elizabeth M Rosethorne; Michelle E Bradley; Toby C Kent; Steven J Charlton
Journal:  Pharmacol Res Perspect       Date:  2015-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.